Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company's product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark.
| Revenue (Most Recent Fiscal Year) | $829.12M |
| Net Income (Most Recent Fiscal Year) | $143.26M |
| PE Ratio (Current Year Earnings Estimate) | 8.29 |
| PE Ratio (Trailing 12 Months) | 10.88 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.30 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.26 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.59 |
| Pre-Tax Margin (Trailing 12 Months) | 21.18% |
| Net Margin (Trailing 12 Months) | 21.11% |
| Return on Equity (Trailing 12 Months) | 11.89% |
| Return on Assets (Trailing 12 Months) | 9.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.33 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.89 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $0.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.80 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 236.57M |
| Free Float | -- |
| Market Capitalization | $2.06B |
| Average Volume (Last 20 Days) | 2865.80 |
| Beta (Past 60 Months) | 1.44 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |